Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective
about
Allele-specific rpoB PCR assays for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smearsAcquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency.Dormancy models for Mycobacterium tuberculosis: A minireviewEuropean union standards for tuberculosis careTranslating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosisEvolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapyIn vitro anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene) isonicotinohydrazide derivatives against isoniazid-resistant strainsEndophytic fungi: a reservoir of antibacterialsHigh rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South AfricaSpontaneous emergence of multiple drug resistance in tuberculosis before and during therapyDynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatmentGlobal transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistanceMolecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complexReduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine modelWhat Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration ProgramsPropargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosisDevelopment of antibiotics and the future of marine microorganisms to stem the tide of antibiotic resistanceSequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon.Molecular patterns of multidrug resistance of Mycobacterium tuberculosis in Georgia.Challenges of antibacterial discoveryPhenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol.Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment.Antibiotics and bacterial resistance in the 21st century.Protein-protein interaction networks suggest different targets have different propensities for triggering drug resistance.High Frequency of First-Line Anti-Tuberculosis Drug Resistance among Persons with Chronic Pulmonary Tuberculosis at a Teaching Hospital Chest Clinic.Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.Platforms for antibiotic discovery.Evaluation of the TB-Biochip oligonucleotide microarray system for rapid detection of rifampin resistance in Mycobacterium tuberculosis.Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen.Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.Versatility of aminoglycosides and prospects for their future.Chemical synthesis enables biochemical and antibacterial evaluation of streptolydigin antibiotics.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia.Recent advances towards identification of new drug targets for Mycobacterium tuberculosis.Pharmacogenomic strategies against resistance development in microbial infections.Epidemiology and challenges to the elimination of global tuberculosis.Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
P2860
Q24669801-C2851F88-F33D-4077-859D-31A3D4664C64Q24814339-2FEBAB4D-5A33-463E-A885-81A08B7F1DFAQ26786040-8C2ED559-BD90-446D-9B6F-66C37A3CEB85Q26823223-646E0EB5-17D6-4530-A07D-A7D025551083Q26824812-8C1A6B83-A10D-41EF-B36F-0D4FE341815FQ27016579-39B8D301-0415-4A1E-B39D-C7EBCBAC6A22Q27024441-728799B8-92A9-4C3A-A34A-BFF47E5E3958Q28083549-357438B1-40F7-42FC-89DC-38D19071BF24Q28365057-411C8200-8CBE-483D-9A63-060A7F522131Q28471774-AD9991A6-EA6B-4361-84CA-1EAA0DC4BBFDQ28477566-6AB641EC-4708-4EB1-A4DA-BB1B9C4A33BEQ28478602-B4B29BE2-D491-4D7E-9FDF-FA10EC2188FBQ28485244-2051E553-719A-4830-B78A-427FD30D232FQ28487335-D36F8C8A-65EF-4020-8E11-8B038718B2AEQ28537876-8FA12642-A1B4-4F74-B1BB-4E26BC04A06DQ28550175-A8228A00-A16C-4847-AB10-94CB338E6DC3Q28553792-D0D53F78-9DD5-4251-8888-74B292C14A21Q28828265-9E1B3F2E-5075-4D4E-B4BF-EAFF3167EBE7Q33597327-9BA3EA55-D3D8-4E08-93B6-EB6BAD110D09Q33703858-3D3DBAED-07EF-4F40-9A2B-DABDDD9DD288Q33793074-21DB08BF-0C36-4ED4-933D-02079565592DQ33836636-E8789328-37A1-4B9C-AD26-9EBB60D8A309Q34065647-F8641D4C-99B5-4E11-B636-81FCC642B4EBQ34156349-4A9D598D-FA3C-4250-AC2F-01E34563B22BQ34237349-38994066-CA31-4FDA-AC92-9072C3A7492AQ34363124-F5B04E29-78A1-4411-BFA5-9543FD37FDFCQ34557101-78DACD5F-5734-4076-8A96-A9342DAC04D3Q34694926-C0FBE39D-6E77-40D5-9180-6564BE4BBD12Q34719995-A0B80A28-8156-4E03-AC5D-AFF48921FE32Q34784058-09B499B7-8698-481C-8BC9-D1BCF5573407Q34932613-A56E2366-D95A-4FAC-A5BF-77250E57150AQ34974987-3D36C35D-C5CD-407D-A0CB-8EF442D39509Q35176271-55A94FD3-B7DB-4DC5-88AC-92B9F4A74A2DQ35217503-AC26AE30-BB94-4883-91AB-FBBF3CEC5364Q35491398-13093966-7FBA-4415-B8AE-9A0E1D6CD94CQ35681236-C3989ABF-D718-4072-8C4A-39262849EE21Q35753354-1D03D8CF-F888-4956-AEA4-9EB422A9AF2AQ35785222-CF3E5772-ABA0-43F6-88EF-805189FDC999Q36073115-077F2889-8F51-40E7-8CBD-996677B5192AQ36092172-8DE889E4-182E-4FCE-B556-7354533A62E2
P2860
Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Evolution of drug resistance i ...... ical and molecular perspective
@ast
Evolution of drug resistance i ...... ical and molecular perspective
@en
Evolution of drug resistance i ...... ical and molecular perspective
@en-gb
Evolution of drug resistance i ...... ical and molecular perspective
@nl
type
label
Evolution of drug resistance i ...... ical and molecular perspective
@ast
Evolution of drug resistance i ...... ical and molecular perspective
@en
Evolution of drug resistance i ...... ical and molecular perspective
@en-gb
Evolution of drug resistance i ...... ical and molecular perspective
@nl
prefLabel
Evolution of drug resistance i ...... ical and molecular perspective
@ast
Evolution of drug resistance i ...... ical and molecular perspective
@en
Evolution of drug resistance i ...... ical and molecular perspective
@en-gb
Evolution of drug resistance i ...... ical and molecular perspective
@nl
P2860
P3181
P1476
Evolution of drug resistance i ...... ical and molecular perspective
@en
P2093
Stephen H Gillespie
P2860
P304
P3181
P356
10.1128/AAC.46.2.267-274.2002
P407
P577
2002-02-01T00:00:00Z